Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-10-18 00:00:00 ET · period of report 2023-10-16 · accession 0001209191-23-053073 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-18 | 2023-10-16 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $374.00 | -13.0K | 22.4K | -37% | -$4.85M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-16 | S | D | 12,962 | $374.00 | 22,425 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $374.00 (range $374.00 to $374.02). |